Clinical and treatment Characterization of patients with Blepharospam in the International Center for Neurological Restoration
Keywords:
blepharospasm, dystonia, focal dystonia, Meige syndrome, botulinum toxin AAbstract
Introduction: Blepharospasm is a chronic and progressive disease that can take on different clinical aspects: from frequent spontaneous blinking and, often, energetic and prolonged, to clonic contractions or tonic contraction of the eyelids of varying intensity and duration, or a mixture of all of them.
Methods: A descriptive, retrospective study was carried out in the period 1996-2016 at the International Center for Neurological Restoration. The sample consisted of 113 patients who met the inclusion criteria: diagnosis of blepharospasm in the study period, age over 18 years and contractures in the orbicularis muscles of the eyelids. Patients with insufficient data in the medical records were excluded. The variables analyzed were: age and sex; etiological cause and treatment. Descriptive statistics techniques were used to analyze the results.
Results: The mean age of onset of the disease was 55, 40 years with a standard deviation of ± 8.70; 73 (64.60%) patients were female and 40 (35.40%) were male. There were 94 (83.1 %) patients whose cause of blepharospasm was idiopathic. 79.64% of patients improved after administration of botulinum toxin type A.
Conclusions: This disease is more frequent in female patients. The most common cause of blepharospasm is idiopathic. The medical treatment of choice is botulinum toxin.
References
1. Newby RE, Thorpe DE, Kempster PA, Alty JE. A History of Dystonia: Ancient to Modern. Mov Disord Clin Pract [Internet]. 2017; 4 (4):478-485. DOI: 10.1002/mdc3.12493
2. Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dystonia: A consensus update. Mov Disord. 2013; 28 (7): 863-873. DOI: 10.1002/mds.25475
3. Sanz Granda A, Martí MJ, Catalán MJ. Análisis coste-utilidad de dos formulaciones de toxina botulínica de tipo A en el tratamiento del blefaroespasmo y la distonía cervical en España. Rev Neurol 2018;67(12):465-472. DOI: 10.33588/rn.6712.2018062
4. Moreno López CL. Diagnóstico y clasificación de la distonía. Acta Neurol Colomb [Internet]. 2017 [acceso: 06/10/2024]; 33(1): 2-8. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0120-87482017000500002&lng=en
5. Anandan C, Jankovic J. Botulinum Toxin in Movement Disorders: An Update. Toxins (Basel). 2021 8; 13 (1): 42. DOI: 10.3390/toxins13010042
6. González Rodríguez VM, González Utrilla AJ, Martín Jiménez JA. Guía de Buena Práctica Clínica en Trastornos del movimiento. Atención Primaria de Calidad. 2005. Disponible en: https://www.cgcom.es/sites/main/files/mig/guia_movimiento.pdf
7. Asociación Médica Mundial AMM. Declaración de Helsinki de la AMM - Principios éticos para las investigaciones médicas en seres humanos. 64ª Asamblea General; 2013 octubre. Fortaleza, Brasil: Asociación Médica Mundial (AMM); 2013. [acceso: 19/01/2020]. Disponible en: https://www.wma.net/es/policies-post/declaracion-de-helsinki-de-la-amm-principios-eticos-para-las-investigaciones-medicas-en-seres-humanos/
8. Martínez Brito BJ, Quintero Pérez M, Reyes Rosa M. Resultados del tratamiento de las distonías focales en el adulto con el uso de toxina botulínica A3. Acta Méd Centro [Internet]. 2015 [acceso: 06/10/2024]; 9 (4) [aprox. 9 p.]. Disponible en: https://revactamedicacentro.sld.cu/index.php/amc/article/view/291
9-Min Lee J, Sun Baek J, Sun Choi H, Joo Kim S, Woo Jang J. Clinical Features of Benign Essential Blepharospasm in Korean Patients. Korean J Ophthalmol. 2018;3 2 (5): 339-343. DOI: https://doi.org/10.3341/kjo.2018.0038
10.Hammer M, Abravanel A, Peckham E, Mahloogi A, Majounie E, Hallet M, et al. Blepharospasm: a genetic screening study in 132 patients. Parkinsonism Relat Disord. 2019; 64: 315–318. DOI: 10.1016/j.parkreldis.2019.04.003
11. O'Riordan S, Raymond D, Lynch T, Saunders-Pullman R, Bressman SB, Daly L, et al. Age at onset as a factor in determining the phenotype of primary torsion dystonia. Neurology. 2004; 63 (8): 1423–1426. DOI: 10.1212/01.wnl.0000142035.26034.c2
12. Yahalom G, Janah A, Rajz G, Eichel R. Therapeutic Approach to Botulinum Injections for Hemifacial Spasm, Synkinesis and Blepharospasm. Toxins. 2022 [acceso: 06/06/2024] 14(5), 362. DOI: https://doi.org/10.3390/toxins14050362
13.Lucas J, Kusyk D, Whiting D. Bilateral pallidal DBS for blepharospasm: A case report and review of the literatura. Surgical Neurology International [Internet]. 2022 [acceso: 06/06/2024]; 13: 200. DOI: 10.25259/SNI_1234_2021
14. Dinjar K, Zubčić V, Kopić A, Kopić V, Popić B, Holik D. Surgical aspect of blepharospasm treatment: a case report. Acta Clin Croat. 2020; 59 (2): 377-381. DOI: 10.20471/acc.2020.59.02.25
15. Bentivoglio AR, Del Grande A, Petracca M, Ialongo T, Ricciardi L. Clinical differences between botulinum neurotoxin type A and B. Toxicon. 2015;107 (Pt A): 77-84. DOI: 10.1016/j.toxicon.2015.08.001
16- Fernández García G. Toxina botulínica y sus aplicaciones clínicas. NPunto [Internet]. 2022. [acceso: 06/07/2024]; 5 (49): 88-110. Disponible en: https://www.npunto.es/revista/49/toxina-botulinica-y-sus-aplicaciones-clinicas
17- García Ruiz-Espiga P, Sanz Cartagena P, Martínez Castrillo JC, Ares B, Avilés Olmos I, Blázquez Estrada M, et al. Mitos y evidencias en el empleo de la toxina botulínica: neurofarmacología y distonías. Revista de Neurología. 2018; 66 (5): 163-172. DOI: https://doi.org/10.33588/.rn.6605.2017110
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Irene González González
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors retain copyright and all unrestricted publication rights.
Medicoquirúrgicas Research is licensed under the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0) and follows the SciELO Publishing Schema (SciELO PS) for publishing in XML format.
You are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material.
The license cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do this in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
Non-Commercial — You may not use the material for commercial purposes.
No Additional Restrictions — You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where their use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all the permissions you need for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
